# EDGAR Filing Document

**Accession Number:** 0001904785
**File Stem:** 0000200406-26-000044
**Filing Date:** 2026-2
**Character Count:** 11087
**Document Hash:** 9d4f58997fa071c6975ba4924f0a5283
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000200406-26-000044.hdr.sgml**: 20260218

**ACCESSION NUMBER**: 0000200406-26-000044

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260213

**FILED AS OF DATE**: 20260218

**DATE AS OF CHANGE**: 20260218

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Swanson James D.
- **CENTRAL INDEX KEY:** 0001904785

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-03215
- **FILM NUMBER:** 26651288

**MAIL ADDRESS:**
- **STREET 1:** ONE JOHNSON & JOHNSON PLAZA
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08933
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JOHNSON & JOHNSON
- **CENTRAL INDEX KEY:** 0000200406
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 221024240
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 1228

**BUSINESS ADDRESS:**
- **STREET 1:** ONE JOHNSON & JOHNSON PLZ
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08933
- **BUSINESS PHONE:** 732-524-2455

**MAIL ADDRESS:**
- **STREET 1:** ONE JOHNSON & JOHNSON PLZ
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08933

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Swanson James D.<br><sub>(Last) (First) (Middle)</sub><br>ONE JOHNSON & JOHNSON PLAZA<br><sub>(Street)</sub><br>NEW BRUNSWICK, NJ 08933<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-13 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP, CIO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>JOHNSON & JOHNSON [ JNJ ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-13 |  | M |  | 447 | A | 0<sup>(1)</sup> | 19298.131 | D |  |
| Common Stock | 2026-02-13 |  | F |  | 143<sup>(2)</sup> | D | $244.55 | 19155.131 | D |  |
| Common Stock | 2026-02-13 |  | M |  | 9412 | A | 0<sup>(3)</sup> | 28567.131 | D |  |
| Common Stock | 2026-02-13 |  | F |  | 3547<sup>(4)</sup> | D | $244.55 | 25020.131 | D |  |
| Common Stock | 2026-02-13 |  | M |  | 19368 | A | $165.89 | 44388.131 | D |  |
| Common Stock | 2026-02-13 |  | S |  | 19368 | D | 243.76<sup>(5)</sup> | 25020.131 | D |  |
| Common Stock | 2026-02-13 |  | M |  | 22191 | A | $162.75 | 47211.131 | D |  |
| Common Stock | 2026-02-13 |  | S |  | 22191 | D | 243.71<sup>(6)</sup> | 25020.131 | D |  |
| Common Stock | 2026-02-15 |  | M |  | 492 | A | 0<sup>(7)</sup> | 25512.131 | D |  |
| Common Stock | 2026-02-15 |  | F |  | 214<sup>(2)</sup> | D | $243.45 | 25298.131 | D |  |
| Common Stock | 2026-02-15 |  | M |  | 709 | A | 0<sup>(8)</sup> | 26007.131 | D |  |
| Common Stock | 2026-02-15 |  | F |  | 309<sup>(2)</sup> | D | $243.45 | 25698.131 | D |  |
| Common Stock | 2026-02-17 |  | M |  | 20521 | A | $164.62 | 46219.131 | D |  |
| Common Stock | 2026-02-17 |  | S |  | 20521 | D | 242.70<sup>(9)</sup> | 25698.131 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Share Units | <sup>(1)</sup> | 2026-02-13 |  | M |  |  | 447 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 447 | $0 | 0 | D |  |
| Performance Share Units | <sup>(3)</sup> | 2026-02-13 |  | M |  |  | 9412 | 2026-02-13 | <sup>(3)</sup> | Common Stock | 9412 | $0 | 0 | D |  |
| Employee Stock Options (Right to Buy) | $165.89 | 2026-02-13 |  | M |  |  | 19368 | 2025-02-14<sup>(10)</sup> | 2032-02-14 | Common Stock | 19368 | $0 | 0 | D |  |
| Employee Stock Options (Right to Buy) | $162.75 | 2026-02-13 |  | M |  |  | 22191 | <sup>(11)</sup> | 2033-02-13 | Common Stock | 22191 | $0 | 0 | D |  |
| Restricted Share Units | <sup>(7)</sup> | 2026-02-15 |  | M |  |  | 492 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 492 | $0 | 491<sup>(12)</sup> | D |  |
| Restricted Share Units | <sup>(8)</sup> | 2026-02-15 |  | M |  |  | 709 | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 709 | $0 | 1418<sup>(12)</sup> | D |  |
| Employee Stock Options (Right to Buy) | $243.45 | 2026-02-15 |  | A |  | 19449 |  | <sup>(11)</sup> | 2036-02-15 | Common Stock | 19449 | $0 | 19449 | D |  |
| Restricted Share Units | <sup>(13)</sup> | 2026-02-15 |  | A |  | 1397 |  | <sup>(13)</sup> | <sup>(13)</sup> | Common Stock | 1397 | $0 | 1397<sup>(12)</sup> | D |  |
| Employee Stock Options (Right to Buy) | $164.62 | 2026-02-17 |  | M |  |  | 20521 | 2024-02-08<sup>(10)</sup> | 2031-02-08 | Common Stock | 20521 | $0 | 0 | D |  |

---

### Footnotes:

(1) Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting.

(2) Shares withheld for payment of taxes upon vesting of RSUs.

(3) Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting.

(4) Shares withheld for payment of taxes upon vesting of PSUs.

(5) This transaction was executed in multiple trades at prices ranging from $243.74 to $243.85.  The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(6) This transaction was executed in multiple trades at prices ranging from $243.64 to $243.895.  The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(7) Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting.

(8) Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.

(9) This transaction was executed in multiple trades at prices ranging from $242.69 to $242.85.  The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(10) Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award  vested and was exercisable on the third anniversary of the grant date.

(11) Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.

(12) Each RSU represents a contingent right to receive one share of Company Common Stock.

(13) Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.

**Signature:** /s/ Joleen Morgan, as attorney-in-fact for James Swanson  
**Date:** 2026-02-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**